The Duke Funding Alert newsletter, published every Monday, provides information on all new and updated grants and fellowships added to the database during the prior week. This listserv is restricted to members of the Duke community.
Schizophrenia and related disorders during mid- to late-life (R01, R21 Clinical Trial Optional)
The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications that will advance translational research to better understand the emergence, trajectory, and outcomes of schizophrenia and related psychotic disorders in mid- to late-life, and to identify targets for future development of prevention and treatment interventions.
This FOA uses the R01 grant mechanism, while the companion FOA (RFA-MH-22-271), uses the R21 mechanism. Investigators proposing high risk/high reward projects that lack preliminary data may be more appropriate for the R21 mechanism.
- Letter of Intent: 30 days prior to the application due date
- Application: Feb. 22, 2023
RFA-MH-22-270 Expiration Date February 23, 2023